Clinical Cancer Research · 2009 · 227 citations · 44 references
These results show that HGF acts mainly as a paracrine factor in HNSCC cells, the HGF/c-Met pathway is frequently up-regulated and functional in HNSCC, and a clinically relevant c-Met TKI shows antitumor activity in vivo. Blocking the HGF/c-Met pathway may be clinically useful for the treatment of HNSCC.
44
Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
Deric L. Wheeler, Shih‐Hao Huang, Tim J. Kruser et al. · Oncogene · 2008 · 537 citations · Full text